Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

<strong>Background<br></strong> The 4-component capsular group B meningococcal vaccine (4CMenB) was licensed as a 4-dose infant schedule but introduced into the United Kingdom as 3 doses at 2, 4, and 12 months of age. We describe the immunogenicity and reactogenicity of the 2 + 1 s...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Valente Pinto, M, O'Connor, D, Galal, U, Clutterbuck, EA, Robinson, H, Plested, E, Bibi, S, Camara Pellisso, S, Hughes, H, Kerridge, S, Mujadidi, YF, Findlow, H, Borrow, R, Snape, MD, Pollard, AJ
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Oxford University Press 2020

Gelijkaardige items

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component.
door: Sheerin, D, et al.
Gepubliceerd in: (2019)

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
door: Davis, K, et al.
Gepubliceerd in: (2021)

A randomized trial assessing the immunogenicity and reactogenicity of two hexavalent infant vaccines concomitantly administered with group b meningococcal vaccine
door: Rajan, M, et al.
Gepubliceerd in: (2022)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
door: Snape, MD, et al.
Gepubliceerd in: (2010)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
door: Shaw, RH, et al.
Gepubliceerd in: (2021)

Invasive Meningococcal Capsular Group Y Disease, England and Wales, 2007–2009
door: Shamez N. Ladhani, et al.
Gepubliceerd in: (2012-01-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
door: Flaxman, A, et al.
Gepubliceerd in: (2021)

The important lessons lurking in the history of meningococcal epidemiology
door: Ray Borrow, et al.
Gepubliceerd in: (2024-12-01)

Methods for predicting vaccine immunogenicity and reactogenicity
door: Patrícia Gonzalez-Dias, et al.
Gepubliceerd in: (2020-02-01)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
door: Kelly, D, et al.
Gepubliceerd in: (2006)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
door: De Whalley, P, et al.
Gepubliceerd in: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
door: de Whalley, P, et al.
Gepubliceerd in: (2013)

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
door: Ramasamy, M, et al.
Gepubliceerd in: (2014)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
door: Dold, C, et al.
Gepubliceerd in: (2023)

Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial.
door: Diggle, L, et al.
Gepubliceerd in: (2006)

Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial
door: Diggle, L, et al.
Gepubliceerd in: (2006)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
door: Waleed H. Mahallawi, et al.
Gepubliceerd in: (2021-12-01)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
door: Pace, D, et al.
Gepubliceerd in: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
door: Milligan, I, et al.
Gepubliceerd in: (2016)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
door: O'Connor, D, et al.
Gepubliceerd in: (2020)

Four component meningococcal capsular Group B vaccine in preterm infants.
door: Sadarangani, M, et al.
Gepubliceerd in: (2017)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
door: Alycia P. Fratzke, et al.
Gepubliceerd in: (2022-05-01)

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
door: O'Connor, D, et al.
Gepubliceerd in: (2017)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
door: Khatami, A, et al.
Gepubliceerd in: (2011)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
door: Timo Vesikari, et al.
Gepubliceerd in: (2020-06-01)

Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants.
door: Collins, C, et al.
Gepubliceerd in: (2005)

Meningococcal polysaccharide-protein conjugate vaccines.
door: Snape, MD, et al.
Gepubliceerd in: (2005)

Control of invasive meningococcal disease: is it achievable?
door: Marshall, H, et al.
Gepubliceerd in: (2016)

The impact of infant Bacille Calmette-Guérin vaccination on the immunogenicity of other vaccines: a randomized exploratory study
door: Maytum, A, et al.
Gepubliceerd in: (2024)

A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
door: Robert T Cartee, et al.
Gepubliceerd in: (2020-01-01)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
door: Daniel O’Connor, et al.
Gepubliceerd in: (2020-11-01)

A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines
door: Jamie Findlow, et al.
Gepubliceerd in: (2019-10-01)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
door: Perrett, K, et al.
Gepubliceerd in: (2009)

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
door: Sadarangani, M, et al.
Gepubliceerd in: (2017)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
door: D. A. Lioznov, et al.
Gepubliceerd in: (2018-06-01)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
door: A.N. Mironov, et al.
Gepubliceerd in: (2010-07-01)

COMPARISON OF REACTOGENICITY AND IMMUNOGENICITY OF LIVE VACCINES AGAINST INFECTIOUS LARYNGOTRACHEITIS
door: S. A. Pokhvalny, et al.
Gepubliceerd in: (2018-05-01)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
door: Chenchit Chayachinda, et al.
Gepubliceerd in: (2023-08-01)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
door: A.N. Mironov, et al.
Gepubliceerd in: (2010-01-01)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
door: Jisun Lee, et al.
Gepubliceerd in: (2023-07-01)